JP2022511554A - メイソインジゴの多形体およびメイソインジゴの改変された製剤 - Google Patents

メイソインジゴの多形体およびメイソインジゴの改変された製剤 Download PDF

Info

Publication number
JP2022511554A
JP2022511554A JP2021532308A JP2021532308A JP2022511554A JP 2022511554 A JP2022511554 A JP 2022511554A JP 2021532308 A JP2021532308 A JP 2021532308A JP 2021532308 A JP2021532308 A JP 2021532308A JP 2022511554 A JP2022511554 A JP 2022511554A
Authority
JP
Japan
Prior art keywords
solid
crystal form
methylisoindigo
solid crystal
particle size
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021532308A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022511554A5 (https=
Inventor
ワン，ロングイ
Original Assignee
ナトロジェン・セラピューティクス・インターナショナル，インコーポレーテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ナトロジェン・セラピューティクス・インターナショナル，インコーポレーテッド filed Critical ナトロジェン・セラピューティクス・インターナショナル，インコーポレーテッド
Publication of JP2022511554A publication Critical patent/JP2022511554A/ja
Publication of JP2022511554A5 publication Critical patent/JP2022511554A5/ja
Priority to JP2024141101A priority Critical patent/JP2024170448A/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/32—Oxygen atoms
    • C07D209/34—Oxygen atoms in position 2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
    • C09B—ORGANIC DYES OR CLOSELY-RELATED COMPOUNDS FOR PRODUCING DYES, e.g. PIGMENTS; MORDANTS; LAKES
    • C09B67/00—Influencing the physical, e.g. the dyeing or printing properties of dyestuffs without chemical reactions, e.g. by treating with solvents grinding or grinding assistants, coating of pigments or dyes; Process features in the making of dyestuff preparations; Dyestuff preparations of a special physical nature, e.g. tablets, films
    • C09B67/0025—Crystal modifications; Special X-ray patterns
    • C—CHEMISTRY; METALLURGY
    • C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
    • C09B—ORGANIC DYES OR CLOSELY-RELATED COMPOUNDS FOR PRODUCING DYES, e.g. PIGMENTS; MORDANTS; LAKES
    • C09B67/00—Influencing the physical, e.g. the dyeing or printing properties of dyestuffs without chemical reactions, e.g. by treating with solvents grinding or grinding assistants, coating of pigments or dyes; Process features in the making of dyestuff preparations; Dyestuff preparations of a special physical nature, e.g. tablets, films
    • C09B67/0096—Purification; Precipitation; Filtration
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2021532308A 2018-12-07 2019-11-21 メイソインジゴの多形体およびメイソインジゴの改変された製剤 Pending JP2022511554A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024141101A JP2024170448A (ja) 2018-12-07 2024-08-22 メイソインジゴの多形体およびメイソインジゴの改変された製剤

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862776965P 2018-12-07 2018-12-07
US62/776,965 2018-12-07
PCT/US2019/062704 WO2020117487A1 (en) 2018-12-07 2019-11-21 Polymorphic form of meisoindigo and modified formulation of meisoindigo

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024141101A Division JP2024170448A (ja) 2018-12-07 2024-08-22 メイソインジゴの多形体およびメイソインジゴの改変された製剤

Publications (2)

Publication Number Publication Date
JP2022511554A true JP2022511554A (ja) 2022-01-31
JP2022511554A5 JP2022511554A5 (https=) 2022-11-28

Family

ID=70974812

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021532308A Pending JP2022511554A (ja) 2018-12-07 2019-11-21 メイソインジゴの多形体およびメイソインジゴの改変された製剤
JP2024141101A Pending JP2024170448A (ja) 2018-12-07 2024-08-22 メイソインジゴの多形体およびメイソインジゴの改変された製剤

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024141101A Pending JP2024170448A (ja) 2018-12-07 2024-08-22 メイソインジゴの多形体およびメイソインジゴの改変された製剤

Country Status (9)

Country Link
US (2) US20220009889A1 (https=)
EP (1) EP3891141A4 (https=)
JP (2) JP2022511554A (https=)
KR (1) KR20210102335A (https=)
CN (2) CN118515598A (https=)
CA (1) CA3121726A1 (https=)
IL (1) IL283703A (https=)
MX (1) MX2021006464A (https=)
WO (1) WO2020117487A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7851300B2 (ja) 2021-04-21 2026-04-24 住友化学株式会社 縮合複素環化合物を用いる衛生害虫の防除方法

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS617254A (ja) * 1984-06-20 1986-01-13 Isukura Sangyo Kk ビスインドリノンおよびそれを主成分とする制癌剤
JP2005516938A (ja) * 2001-12-13 2005-06-09 ナトロジェン・セラピューティクス・インコーポレーテッド イソインジゴ、インジゴおよびインジルビンの誘導体、ならびに癌治療における使用
JP2007522114A (ja) * 2004-01-12 2007-08-09 ナトロジェン・セラピューティクス・インコーポレーテッド 炎症関連疾患の治療法
US20160243077A1 (en) * 2012-03-23 2016-08-25 Dennis M. Brown Compositions and methods to improve the therapeutic benefit of indirubin and analogs thereof, including meisoindigo

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7582670B2 (en) * 2001-12-13 2009-09-01 Natrogen Therapeutics, Inc. Methods of treating an inflammatory-related disease
PT106237B (pt) * 2012-03-30 2015-03-19 Hovione Farmaci Ncia S A Produção de partículas substancialmente monodispersas utilizando moagem e separação por membranas
CN106176720A (zh) * 2016-08-17 2016-12-07 武汉大学 甲异靛在制备抗炎药物中的应用

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS617254A (ja) * 1984-06-20 1986-01-13 Isukura Sangyo Kk ビスインドリノンおよびそれを主成分とする制癌剤
JP2005516938A (ja) * 2001-12-13 2005-06-09 ナトロジェン・セラピューティクス・インコーポレーテッド イソインジゴ、インジゴおよびインジルビンの誘導体、ならびに癌治療における使用
JP2007522114A (ja) * 2004-01-12 2007-08-09 ナトロジェン・セラピューティクス・インコーポレーテッド 炎症関連疾患の治療法
US20160243077A1 (en) * 2012-03-23 2016-08-25 Dennis M. Brown Compositions and methods to improve the therapeutic benefit of indirubin and analogs thereof, including meisoindigo

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
CHENG, XINLAI; ET AL.: "Methylisoindigo preferentially kills cancer stem cells by interfering cell metabolism via inhibition", MOLECULAR ONCOLOGY, vol. 10(6), JPN7023004761, 2016, pages 806 - 824, ISSN: 0005215353 *
PATRIC STAHLY: "医薬品の塩選択、結晶多形のスクリーニングの重要性について", 薬剤学, vol. 66, no. 6, JPN6015024142, 2006, pages 435 - 439, ISSN: 0005312465 *
SEO, DA YOUNG; ROH, HWA JUNG; MIN, BEOM KYU; KIM, JAE NYOUNG: "Facile Synthesis of Isoindigo Derivatives from 3-Indolyl-2-Oxindoles with DDQ.", BULLETIN OF THE KOREAN CHEMICAL SOCIETY, vol. 38(12), JPN7023004763, 2017, pages 1519 - 1522, ISSN: 0005312464 *
ZHAO, PING; ET AL.: "Design, synthesis and biological evaluation of N-alkyl or aryl substituted isoindigo derivatives as", EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, vol. 86, JPN7023004762, 2014, pages 165 - 174, ISSN: 0005215352 *

Also Published As

Publication number Publication date
US20250084035A1 (en) 2025-03-13
JP2024170448A (ja) 2024-12-10
IL283703A (en) 2021-07-29
EP3891141A1 (en) 2021-10-13
CA3121726A1 (en) 2020-06-11
US20220009889A1 (en) 2022-01-13
CN113365990A (zh) 2021-09-07
KR20210102335A (ko) 2021-08-19
WO2020117487A1 (en) 2020-06-11
EP3891141A4 (en) 2022-10-12
CN118515598A (zh) 2024-08-20
MX2021006464A (es) 2021-09-28

Similar Documents

Publication Publication Date Title
US11229620B2 (en) 3-methanesulfonylpropionitrile for treating inflammation and/or pain
CN110088105B (zh) Jak家族激酶的小分子抑制剂
EA037447B1 (ru) Способ лечения эозинофильных заболеваний
US20250084035A1 (en) Polymorphic form of meisoindigo and modified formulation of meisoindigo
CN112313233A (zh) Jak家族激酶的小分子抑制剂
CN111635309B (zh) 一种新型解热镇痛药物及其制备方法和用途
CN111635315B (zh) 一种解热镇痛药物及其制备方法和用途
JPH0272163A (ja) 皮膚および粘膜上皮の疾患の治療のための４‐キノリンカルボン酸誘導体
US11236041B2 (en) Type-G crystal form of fenolamine, preparation method, composition and use thereof
CN114644642A (zh) 一种噻吩并吡啶化合物的晶型a、制备方法及其药物组合物
JP5698741B2 (ja) １３ａ−（Ｓ）脱酸チロホリニンの塩、医薬組成物と用途
TWI435727B (zh) 調節細胞激素分泌之用途
KR20210042041A (ko) 페놀라민 b형 결정, 제조 방법과 그의 조성물 및 용도
US11466025B2 (en) Thienopyridine derivatives containing unsaturated aliphatic olefinic bond, preparation method and use thereof
CN115244054B (zh) 次黄嘌呤化合物的晶体
WO2025002076A1 (zh) 一种mk2抑制剂在制备预防和/或治疗疾病药物中的应用
CN110840898B (zh) 光稳定化药物组合物及其制备方法和制药用途
CN120392771A (zh) 小分子化合物及其在制备治疗24p3R介导的疾病的药物中的应用
CN119954867A (zh) 一种含As（III）化合物及其制备方法与应用
CN110117279A (zh) (13aS)-3-新戊酰氧基-6,7-二甲氧基菲并吲哚里西啶的晶B型
CN110117280A (zh) (13aS)-3-新戊酰氧基-6,7-二甲氧基菲并吲哚里西啶的晶A型
WO2018223859A1 (zh) 氮杂环丁烷衍生物的固体形式及其制备方法和用途

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221117

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20221117

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20231124

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20231211

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240311

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20240311

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20240425